Kanemitsu et al. recently showed a positive correlation between VIP expression in subchondral bone and osteoarthritis progression, indicating the peptide’s involvement in joint pathology and suggesting the potential use of antagonists of VIP signalling to counteract the pathology [108]. The gene discussed is VIP; the disease is osteoarthritis.